ASPIRA PATHLAB & DIAGNOSTICS | INDO-GLOBAL ENT. | ASPIRA PATHLAB & DIAGNOSTICS / INDO-GLOBAL ENT. |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -13.4 | -31.9 | - | View Chart |
P/BV | x | 2.6 | 1.4 | 176.9% | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
ASPIRA PATHLAB & DIAGNOSTICS INDO-GLOBAL ENT. |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASPIRA PATHLAB & DIAGNOSTICS Mar-23 |
INDO-GLOBAL ENT. Mar-20 |
ASPIRA PATHLAB & DIAGNOSTICS / INDO-GLOBAL ENT. |
5-Yr Chart Click to enlarge
|
||
High | Rs | 75 | 20 | 367.6% | |
Low | Rs | 26 | 20 | 125.7% | |
Sales per share (Unadj.) | Rs | 14.0 | 0 | - | |
Earnings per share (Unadj.) | Rs | -0.1 | -0.7 | 13.2% | |
Cash flow per share (Unadj.) | Rs | 1.5 | -0.7 | -222.2% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 12.4 | 11.1 | 111.7% | |
Shares outstanding (eoy) | m | 10.29 | 6.37 | 161.5% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.6 | 0 | - | |
Avg P/E ratio | x | -583.7 | -31.1 | 1,875.2% | |
P/CF ratio (eoy) | x | 34.6 | -31.1 | -111.2% | |
Price / Book Value ratio | x | 4.1 | 1.8 | 221.0% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 518 | 130 | 398.6% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 56 | 1 | 11,186.0% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 145 | 0 | - | |
Other income | Rs m | 3 | 0 | - | |
Total revenues | Rs m | 148 | 0 | - | |
Gross profit | Rs m | 16 | -1 | -1,091.1% | |
Depreciation | Rs m | 16 | 0 | - | |
Interest | Rs m | 4 | 1 | 604.3% | |
Profit before tax | Rs m | -1 | -2 | 41.2% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 0 | 2 | 0.0% | |
Profit after tax | Rs m | -1 | -4 | 21.3% | |
Gross profit margin | % | 11.0 | 0 | - | |
Effective tax rate | % | 0 | -93.4 | 0.0% | |
Net profit margin | % | -0.6 | 0 | - |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 59 | 0 | 146,400.0% | |
Current liabilities | Rs m | 16 | 7 | 230.4% | |
Net working cap to sales | % | 29.5 | 0 | - | |
Current ratio | x | 3.7 | 0 | 63,547.8% | |
Inventory Days | Days | 88 | 0 | - | |
Debtors Days | Days | 590 | 0 | - | |
Net fixed assets | Rs m | 115 | 80 | 143.7% | |
Share capital | Rs m | 103 | 64 | 161.6% | |
"Free" reserves | Rs m | 25 | 7 | 351.5% | |
Net worth | Rs m | 128 | 71 | 180.4% | |
Long term debt | Rs m | 10 | 2 | 402.5% | |
Total assets | Rs m | 173 | 80 | 216.9% | |
Interest coverage | x | 0.8 | -2.1 | -37.3% | |
Debt to equity ratio | x | 0.1 | 0 | 223.2% | |
Sales to assets ratio | x | 0.8 | 0 | - | |
Return on assets | % | 1.9 | -4.4 | -43.5% | |
Return on equity | % | -0.7 | -5.9 | 11.8% | |
Return on capital | % | 2.4 | -2.0 | -119.6% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 0 | 0 | - | |
Fx outflow | Rs m | 0 | 0 | - | |
Net fx | Rs m | 0 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 0 | -1 | 8.8% | |
From Investments | Rs m | 2 | NA | - | |
From Financial Activity | Rs m | -9 | 1 | -682.5% | |
Net Cashflow | Rs m | -8 | 0 | - |
Indian Promoters | % | 18.7 | 2.8 | 663.8% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 0.0 | - | |
FIIs | % | 0.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 81.3 | 97.2 | 83.6% | |
Shareholders | 1,512 | 543 | 278.5% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASPIRA PATHLAB & DIAGNOSTICS With: APOLLO HOSPITALS DR. LAL PATHLABS METROPOLIS HEALTHCARE KIMS NARAYANA HRUDAYALAYA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | ASPIRA PATHLAB & DIAGNOSTICS | INDO-GLOBAL ENT. | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -2.14% | -4.76% | 0.45% |
1-Month | -8.93% | 6.24% | 2.55% |
1-Year | -3.33% | -13.28% | 56.14% |
3-Year CAGR | 1.86% | -7.78% | 15.22% |
5-Year CAGR | -1.91% | -4.74% | 19.63% |
* Compound Annual Growth Rate
Here are more details on the ASPIRA PATHLAB & DIAGNOSTICS share price and the INDO-GLOBAL ENT. share price.
Moving on to shareholding structures...
The promoters of ASPIRA PATHLAB & DIAGNOSTICS hold a 18.7% stake in the company. In case of INDO-GLOBAL ENT. the stake stands at 2.8%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of ASPIRA PATHLAB & DIAGNOSTICS and the shareholding pattern of INDO-GLOBAL ENT..
Finally, a word on dividends...
In the most recent financial year, ASPIRA PATHLAB & DIAGNOSTICS paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
INDO-GLOBAL ENT. paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of ASPIRA PATHLAB & DIAGNOSTICS , and the dividend history of INDO-GLOBAL ENT..
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.